ArticleSchizophrenia bulletin2017
Striatal and Extrastriatal Dopamine Transporter Availability in Schizophrenia and Its Clinical Correlates: A Voxel-Based and High-Resolution PET Study.
Article in Schizophrenia bulletin, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Dopamine Transporter and Reward Anticipation in a Dimensional Perspective: A Multimodal Brain Imaging Study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Trial
- Resolving the heterogeneity of dopamine subsystems dysfunction in schizophrenia: a PET meta-analysis.Schizophrenia (Heidelberg, Germany) · 2025Review
- Role of Glial Trace Amine Associated Receptor 1 (TAAR1) and Microbiota in Schizophrenia.Neurochemical research · 2025Review
- Stable Dopamine-Signaling mRNA Co-Expression in the Substantia Nigra Is Deregulated in Pathological Conditions, but Not in Dopamine Transporter Knockout Rats.Biomolecules · 2025Article
- Combinations and Temporal Associations Among Precursor Symptoms Before a First Episode of Psychosis.Schizophrenia bulletin · 2024Article
- Dopamine and serotonin alterations byNutrition research and practice · 2023Article
- Potential diagnostic biomarkers for schizophrenia.Medical review (2021) · 2022Review
- Future Prospects of Positron Emission Tomography-Magnetic Resonance Imaging Hybrid Systems and Applications in Psychiatric Disorders.Pharmaceuticals (Basel, Switzerland) · 2022Review
- The bimodal mechanism of interaction between dopamine and mitochondria as reflected in Parkinson's disease and in schizophrenia.Journal of neural transmission (Vienna, Austria : 1996) · 2020Review
- Dopamine and glutamate in schizophrenia: biology, symptoms and treatment.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2020Article
- Dopamine Receptor Subtypes, Physiology and Pharmacology: New Ligands and Concepts in Schizophrenia.Frontiers in pharmacology · 2020Review
- Diffusion kurtosis imaging of gray matter in schizophrenia.Cortex; a journal devoted to the study of the nervous system and behavior · 2019Article
- The Story of the Dopamine Transporter PET Tracer LBT-999: From Conception to Clinical Use.Frontiers in medicine · 2019Review
- Activation of brainstem and midbrain nuclei during cognitive control in medicated patients with schizophrenia.Human brain mapping · 2019Article
- Neurobiological Determinants of Tobacco Smoking in Schizophrenia.Frontiers in psychiatry · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroimaging studies investigating dopamine (DA) function widely support the hypothesis of presynaptic striatal DA hyperactivity in schizophrenia. However, published data on the striatal DA transporter (DAT) appear less consistent with this hypothesis, probably partly due to methodological limitations. Moreover, DAT in extrastriatal regions has been very poorly investigated in the context of schizophrenia. In order to address these issues, we used a high resolution positron emission tomograph and the selective DAT radioligand [11C]PE2I, coupled with a whole brain voxel-based analysis method to investigate DAT availability in striatal but also extra-striatal regions in 21 male chronic schizophrenia patients compared to 30 healthy male controls matched by age. We found higher DAT availability in schizophrenia patients in midbrain, striatal, and limbic regions. DAT availability in amygdala/hippocampus and putamen/pallidum was positively correlated with hallucinations and suspiciousness/persecution, respectively. These results are consistent with an increase of presynaptic DA function in patients with schizophrenia, and support the involvement of both striatal and extrastriatal DA dysfunction in positive psychotic symptoms. The study also highlights the whole brain voxel-based analysis method to explore DA dysfunction in schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.